Abstract
Tuberculosis continues to be a deadly infectious disease, mainly due to the existence of persistent bacterial populations that survive drug treatment and obstruct complete eradication of infection. The enzymes GlgE and GlgB, which are involved in the glycan pathway, have recently been identified as promising drug targets for combating persistent bacillus strains. In the glycan pathway, enzymes GlgE, GlgA, and Tre-xyz produce linear α-glucans, which are then converted to essential branched α-glucan by GlgB. This α-glucan is a vital cell-wall and storage polysaccharide, critical for Mtb virulence and persistence. We highlight recent insights into the significance of both GlgE and GlgB in the glycan pathway and also discuss drug strategies for tuberculosis such as polypharmcological targeting of GlgB and GlgE. Small molecule-based modulation of GlgB and GlgE to boost the design and development of novel and improved drugs for more selective and efficient targeting of tuberculosis are also discussed.
Keywords: α-glucan, capsular glucan, GlgB, GlgE, glycogen branching enzyme, high-throughput screening assays, horseradish peroxidase (HRPO) assay, iodine assay, Mtb, polypharamcology, small molecule.
Current Medicinal Chemistry
Title:α-Glucan Pathway as a Novel Mtb Drug Target: Structural Insights and Cues for Polypharmcological Targeting of GlgB and GlgE
Volume: 21 Issue: 35
Author(s): Pushpa Agrawal, Pawan Gupta, Kunchithapadam Swaminathan and Raman Parkesh
Affiliation:
Keywords: α-glucan, capsular glucan, GlgB, GlgE, glycogen branching enzyme, high-throughput screening assays, horseradish peroxidase (HRPO) assay, iodine assay, Mtb, polypharamcology, small molecule.
Abstract: Tuberculosis continues to be a deadly infectious disease, mainly due to the existence of persistent bacterial populations that survive drug treatment and obstruct complete eradication of infection. The enzymes GlgE and GlgB, which are involved in the glycan pathway, have recently been identified as promising drug targets for combating persistent bacillus strains. In the glycan pathway, enzymes GlgE, GlgA, and Tre-xyz produce linear α-glucans, which are then converted to essential branched α-glucan by GlgB. This α-glucan is a vital cell-wall and storage polysaccharide, critical for Mtb virulence and persistence. We highlight recent insights into the significance of both GlgE and GlgB in the glycan pathway and also discuss drug strategies for tuberculosis such as polypharmcological targeting of GlgB and GlgE. Small molecule-based modulation of GlgB and GlgE to boost the design and development of novel and improved drugs for more selective and efficient targeting of tuberculosis are also discussed.
Export Options
About this article
Cite this article as:
Agrawal Pushpa, Gupta Pawan, Swaminathan Kunchithapadam and Parkesh Raman, α-Glucan Pathway as a Novel Mtb Drug Target: Structural Insights and Cues for Polypharmcological Targeting of GlgB and GlgE, Current Medicinal Chemistry 2014; 21 (35) . https://dx.doi.org/10.2174/0929867321666140826120449
DOI https://dx.doi.org/10.2174/0929867321666140826120449 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Virtual Screening on Analogs of 2 Methyl Heptyl Isonicotinate as GlmU Inhibitors of Mycobacterium tuberculosis
Current Enzyme Inhibition Inhibitors of Bacterial Transcription are Compounds for Potent Antimicrobial Drugs
Current Pharmaceutical Biotechnology Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry Pulmonary Surfactant Proteins A and D: Innate Immune Functions and Biomarkers for Lung Diseases
Current Pharmaceutical Design Pleural Involvement Due to Metastatic Melanoma: A Rare Complication and Literature Review
Current Respiratory Medicine Reviews Neopterin as a Marker for Immune System Activation
Current Drug Metabolism DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers MRI of the Small and Large Bowel
Current Medical Imaging Aminopyrimidinimino Isatin Analogues: Design and Synthesis of Novel Non- Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Broad- Spectrum Anti-Microbial Properties
Medicinal Chemistry Synthesis and Evaluation of Tetrazole-BasedHydrazone Derivatives Bearing a Pyridine Moiety as Antimicrobial Agents
Letters in Drug Design & Discovery Evaluation and Prediction of Early Alzheimer’s Disease Using a Machine Learning-based Optimized Combination-Feature Set on Gray Matter Volume and Quantitative Susceptibility Mapping
Current Alzheimer Research Microwave Induced One Pot Ugi Multicomponent Reaction of Fluoroquino Lone Scaffolds: Their Biological Evaluation
Current Green Chemistry Bactericidal and Hemolytic Activities of Synthetic Peptides Derived from Granulysin
Protein & Peptide Letters Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters In Silico (3D-QSAR) Designed, Study, Synthesis and Anti-tubercular Evaluation of Pyrazolo-Pyrimidine Derivatives
Anti-Infective Agents Editorial (Thematic Issue: Role of Data and Methods in Chemoinformatics for Virtual Screening)
Combinatorial Chemistry & High Throughput Screening Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights
Current Pharmaceutical Biotechnology